These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 28883219)

  • 21. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.
    Han EJ; Lee SE; Kim SH; Sohn HS; Jung SE; Park G; Choi BO; Lee SN; Yang SW; Han K; Cho SG
    Ann Hematol; 2011 Sep; 90(9):1075-82. PubMed ID: 21336624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
    Gleeson M; Counsell N; Cunningham D; Chadwick N; Lawrie A; Hawkes EA; McMillan A; Ardeshna KM; Jack A; Smith P; Mouncey P; Pocock C; Radford JA; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Ann Oncol; 2017 Oct; 28(10):2511-2516. PubMed ID: 28961838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
    Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.
    Yoo KH; Lee JY; Lim SH; Ko YH; Kim SJ; Kim WS
    Acta Haematol; 2015; 133(2):179-82. PubMed ID: 25323539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients.
    Shin HJ; Yoon DH; Lee HS; Oh SY; Yang DH; Kang HJ; Chong SY; Park Y; Do Y; Lim SN; Jo JC; Lee WS; Chung JS;
    Exp Hematol; 2016 Jan; 44(1):3-13. PubMed ID: 26325332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An apparently primary lymphoma of the testicle].
    Belbusti F; Signoretti P; Tondi MR; Sparaventi G
    G Chir; 1991; 12(8-9):438-40. PubMed ID: 1721520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
    Cheah CY; Herbert KE; O'Rourke K; Kennedy GA; George A; Fedele PL; Gilbertson M; Tan SY; Ritchie DS; Opat SS; Prince HM; Dickinson M; Burbury K; Wolf M; Januszewicz EH; Tam CS; Westerman DA; Carney DA; Harrison SJ; Seymour JF
    Br J Cancer; 2014 Sep; 111(6):1072-9. PubMed ID: 25072255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
    Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
    Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Primary testicular malignant lymphoma in a hemodialysis patient : a case report].
    Nakatsuji H; Sakaki M; Hamao T
    Hinyokika Kiyo; 2015 Feb; 61(2):67-70. PubMed ID: 25812596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful autologous peripheral blood stem cell transplantation for a patient with primary adrenal lymphoma with hemophagocytic syndrome.
    Uehara T; Yokota A; Onoda M; Yamamoto K; Terano T
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):184-7. PubMed ID: 18650184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.